Abstracts tagged "cytokines"

Abstract Number: 034 • 2023 Pediatric Rheumatology Symposium
STAT3 Gain-of-function Syndrome Mutations Are Susceptible to JAK Inhibition Despite a Spectrum of Potency
Herda Ona¹, Justin Branch², Isabella Osuna¹, Priscilla vasquez², Anaid Reyes¹, Phillip Baker¹, Michael Clowers¹, Stephanie Wood¹ and Tiphanie Vogel¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: STAT3 gain-of-function (GOF) syndrome is a rare inborn error of immunity that leads to early-onset lymphoproliferation, autoimmune cytopenias, multi-solid organ autoimmunity, hypogammaglobulinemia, and short…
Abstract Number: 037 • 2023 Pediatric Rheumatology Symposium
Transcriptional Analysis of CD14+ Monocytes During Macrophage Activation Syndrome Highlights Role for Interferons and RNA Sensing in Monocytes
Susan Canny¹, Hannah DeBerg², Griffin Gessay², Ailing Lu³, Mary Eckert¹, Andrea La Bella⁴, Susan Shenoi⁵, Joyce Hui-Yuen⁶, Betsy Barnes⁷ and Jessica Hamerman², ¹Seattle Children's Hospital, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Northwell Health, Cohen Children's Medical Center, New Hyde Park, NY, ⁵Seattle Children's Hospital, Seattle, WA, ⁶Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁷Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY
Background/Purpose: Macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (HLH), is a potentially fatal complication of rheumatic diseases. MAS is a dysfunctional hyperinflammatory…
Abstract Number: 0266 • ACR Convergence 2022
Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression
Judith Heutz¹, Cleo Rogier², Ellis Niemantsverdriet³, Susan van den Eeden⁴, Pascal de Jong⁵, Annemieke Geluk⁶ and Annette van der Helm-van Mil⁷, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Erasmus MC, Rotterdam, Netherlands, ³LUMC, Leiden, Netherlands, ⁴Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁵ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁶Leiden University Medical Center (LUMC), Leiden, Zuid-Holland, Netherlands, ⁷Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Autoantibody responses rise years before onset of inflammatory arthritis (IA) and are stable during transitioning from clinically suspect arthralgia (CSA) to IA (1). Cytokine…
Abstract Number: 0652 • ACR Convergence 2022
Serum from Patients with SLE and Anti-MDA5 Antibody-Positive Dermatomyositis Induce Shared Monocyte Cytokine Signature Through Type 1 Interferon Pathway
Shohei Nakamura, Yuko okamoto, Yasuhiro Katsumata and Masayoshi Harigai, Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
Background/Purpose: Although type 1 interferon (IFN) plays a pivotal role in the pathogenesis of systemic lupus erythematosus (SLE) and polymyositis/dermatomyositis (PM/DM) [1] as typically evidenced…
Abstract Number: 1686 • ACR Convergence 2022
Post-translational Modification of Matrix-gla Protein with Malondialdehyde-Acetaldehyde Alters Cellular Responses by Human Fibroblasts
Austin Ragland¹, Michael Duryee¹, nozima Aripova¹, Spencer Jones¹, Ted Mikuls² and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Post-translational modifications with malondialdehyde-acetaldehyde (MAA) alter protein structure and function, inducing pro-inflammatory and pro-fibrotic responses characteristic of rheumatoid arthritis (RA). Matrix-gla protein (MGP) chelates…
Abstract Number: 0499 • ACR Convergence 2022
Drivers of Heterogeneity in Synovial Fibroblasts in Rheumatoid Arthritis
Melanie Smith¹, Vianne Gao², Edward DiCarlo¹, Susan Goodman¹, Thomas Norman², Laura Donlin¹, Christina Leslie² and Alexander Rudensky², ¹Hospital for Special Surgery, New York, NY, ²Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is characterized by hyperplasia of both the synovial lining, which forms the synovial fluid interface, as well as the synovial sublining,…
Abstract Number: 0666 • ACR Convergence 2022
HRES-1/Rab4 Controls the Overexpression of CD38 and Depletion of IL-2 in CD4+ T Cells; Potential Involvement in Proinflammatory Lineage Development in SLE
Seong Hee (Joy) Park¹, Akshay Patel² and Andras Perl³, ¹Upstate Medical University, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
Abstract Number: 1691 • ACR Convergence 2022
Pentagalloyl Glucose Inhibits MSU-Induced Inflammation via Transforming Growth Factor-β-Activated Kinase 1 (TAK1)
Paul Panipinto, Anil Singh, Farheen Sultan Shaikh and Salahuddin Ahmed, Washington State University, Spokane, WA
Background/Purpose: Gout disease flares occur when primed macrophages interact with and phagocytose monosodium urate crystals (MSU), activating IL-1β via the NLRP3 inflammasome. Abrogation of inflammasome…
Abstract Number: 0559 • ACR Convergence 2022
JAK Inhibitor Withdrawal Causes a Transient Proinflammatory Signaling Cascade in Minor Salivary Gland Mesenchymal Stromal Cells
Ilya Gurevic, jacques Galipeau and Sara McCoy, University of Wisconsin, Madison, WI
Background/Purpose: Sjögren's Disease (SjD) has high glandular IFNg levels, associated with disease activity and lymphoma risk. We previously showed IFNg-stimulated minor salivary gland (SG)-mesenchymal stromal…
Abstract Number: 0689 • ACR Convergence 2022
Type I Interferon Stimulated Genes Identify Different Phenotypes of Antiphospholipid Syndrome Patients
Irene Cecchi¹, Massimo Radin², Alice Barinotti², Silvia Grazietta Foddai², Elena Rubini², Ana Suárez³, Simone Baldovino², Elisa Menegatti², Dario Roccatello², Savino Sciascia¹ and Javier Rodríguez-Carrio⁴, ¹University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³University of Oviedo, Oviedo, Spain, ⁴University of Oviedo,, Oviedo, Spain
Background/Purpose: At present, a limited number of evidencesis available on the specific role of Type I Interferons (IFN) activation in antiphospholipid antibodies (aPL) positive patients,…
Abstract Number: 1700 • ACR Convergence 2022
IL-21/STAT3 Pathway Mediated Th2-like Vδ2 T Cells Promote Plasmablasts Differentiation in IgG4-Related Disease
Jieqiong Li¹ and Wen Zhang², ¹Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, ²Peking Union Medical College Hospital, Beijing, China
Background/Purpose: To explore the phenotype and role of gamma delta (γδ) T cells in the pathogenesis of IgG4-related disease (IgG4-RD), focusing on the effect on…
Abstract Number: 0569 • ACR Convergence 2022
Cytokine Storm Susceptibility Factors IL-18 and Cytotoxic Impairment Converge on Pathologic CD8 T-cell Hyperactivation
Emily Landy¹, Scott Canna², Paul Tsoukas³, Vinh Dang² and Jemy Varghese², ¹University of Pittsburgh, Pittsburgh, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Mounting evidence suggests partial defects in cytotoxicity-related genes may promote hyperinflammation in Macrophage Activation Syndrome (MAS) patients, who uniformly have highly-elevated IL-18. In mice,…
Abstract Number: 0806 • ACR Convergence 2022
Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression
Inés Pérez Sancristóbal¹, María Paula Álvarez Hernández², Silvia Sanchez - Ramon³, Cristina Martinez⁴, Eduardo de la Fuente³, Concepcion Morado⁴, Dalifer Freites Nuñez², Benjamin Fernandez Gutierrez⁵ and Gloria Candelas⁴, ¹Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Department of Clinical Immunology, IML and IdSSC, Hospital Clínico San Carlos, Madrid, Spain, ⁴Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁵Hospital Clínico San Carlos, Rheumatology Deparment, Madrid, Spain
Background/Purpose: Infections in patients with systemic autoimmune disease (SAD) are associated with immune dysfunction, disease activity and immunosuppression. Synthetic and biologic disease-modifying drugs (DMARDs) have…
Abstract Number: 1729 • ACR Convergence 2022
SLAMF4+ CCR5+ Effector Memory CD4+ T Cells Are Polyfunctional, Resistant to Exhaustion, and Expanded in Rheumatoid Arthritis
Mégane Lacaud¹, Houda-Ghozlane Bouzidi¹, Magali Breckler², Delphine Lemeiter², Johanna Sigaux³, Luca Semerano⁴, Marie-Christophe Boissier⁵, Natacha Bessis⁶ and Jerome Biton⁷, ¹Sorbonne Paris Nord University, Inserm U1125, Bobigny, France, ²Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, ³Avicenne Hospital, Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, ⁴Hopital Avicenne - AP-HP, Sorbonne Paris Nord University, INSERM UMR1125, Bobigny Cedex, France, ⁵INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, ⁶INSERM 1125 and University Sorbonne Paris Nord, Bobigny, France, ⁷INSERM UMR 1125, Sorbonne Paris Nord University, Bobigny, France
Background/Purpose: CD4+ Foxp3- conventional T cells (Tconv) play a key role in the inflammatory process involved in rheumatoid arthritis (RA). Usually, chronic stimulation of T…
Abstract Number: 0581 • ACR Convergence 2022
Mutants Improving Stability Enhance the Potency of Treg-Selective IL-2 Mutein for the Treatment of Autoimmune Disorders
Yingying Hu¹, Hu Ge¹, Yuxi Yan¹, Yun Zhang², Xiaoxing Huang¹, Zhenna Gao², Yiming Kou², Mi Ye², Lei Zhou¹, Siyuan Shao¹, Bowei Yin¹, Zhenzhen Li¹, Yayuan Fu¹, Wenqing Yang¹, Zhuoxiao Cao¹ and Renhong Tang¹, ¹Simcere Pharmaceutical Group, Shanghai, China, ²Simcere Pharmaceutical Group, Nanjing, China
Background/Purpose: Low-dose IL-2 with enhanced sensitivity to Treg cells has been proved to be safe and efficacious in multiple autoimmune disorders (AIDs) including SLE, RA,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].